Crysvita (burosumab-twza) — Coverage Criteria for X-linked hypophosphatemia (XLH) and FGF23-related hypophosphatemia in TIO
Customize your policy alerts
Sign up for sierra health and life Policy 2026D0071O alerts
Get alerted when Policy 2026D0071O changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical necessity criteria, prior authorization, and coding for Crysvita (burosumab-twza) for treatment of X-linked hypophosphatemia (XLH) and FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) for applicable UnitedHealthcare commercial and individual exchange plans.
Policy transferred to shared template and applied to UnitedHealthcare Commercial and Individual Exchange plans; prior authorization requirements follow the member-specific plan.
No material clinical or coverage changes beyond template update were identified in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.